Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium

Mia M. Gaudet, Myrto Barrdahl, Sara Lindström, Ruth C. Travis, Paul L. Auer, Julie E. Buring, Stephen J. Chanock, A. Heather Eliassen, Susan M. Gapstur, Graham G. Giles, Marc Gunter, Christopher Haiman, David J. Hunter, Amit D. Joshi, Rudolf Kaaks, Kay Tee Khaw, I. Min Lee, Loic Le Marchand, Roger L. Milne, Petra H M PeetersMalin Sund, Rulla Tamimi, Antonia Trichopoulou, Elisabete Weiderpass, Xiaohong R. Yang, Ross L. Prentice, Heather Spencer Feigelson, Federico Canzian, Peter Kraft

Research output: Contribution to journal › Article

Abstract

Current use of menopausal hormone therapy (MHT) has important implications for postmenopausal breast cancer risk, and observed associations might be modified by known breast cancer susceptibility loci. To provide the most comprehensive assessment of interactions of prospectively collected data on MHT and 17 confirmed susceptibility loci with invasive breast cancer risk, a nested case–control design among eight cohorts within the NCI Breast and Prostate Cancer Cohort Consortium was used. Based on data from 13,304 cases and 15,622 controls, multivariable-adjusted logistic regression analyses were used to estimate odds ratios (OR) and 95 % confidence intervals (CI). Effect modification of current and past use was evaluated on the multiplicative scale. P values −3 were considered statistically significant. The strongest evidence of effect modification was observed for current MHT by 9q31-rs865686. Compared to never users of MHT with the rs865686 GG genotype, the association between current MHT use and breast cancer risk for the TT genotype (OR 1.79, 95 % CI 1.43–2.24; Pinteraction = 1.2 × 10−4) was less than expected on the multiplicative scale. There are no biological implications of the sub-multiplicative interaction between MHT and rs865686. Menopausal hormone therapy is unlikely to have a strong interaction with the common genetic variants associated with invasive breast cancer.

Original languageEnglish (US)
Pages (from-to)531-540
Number of pages10
JournalBreast Cancer Research and Treatment
Volume155
Issue number3
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Hormones
Breast Neoplasms
Therapeutics
Genotype
Confidence Intervals
Logistic Models
Odds Ratio
Regression Analysis

Keywords

  • Breast cancer
  • Genetic variation
  • Menopausal hormone therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. / Gaudet, Mia M.; Barrdahl, Myrto; Lindström, Sara; Travis, Ruth C.; Auer, Paul L.; Buring, Julie E.; Chanock, Stephen J.; Heather Eliassen, A.; Gapstur, Susan M.; Giles, Graham G.; Gunter, Marc; Haiman, Christopher; Hunter, David J.; Joshi, Amit D.; Kaaks, Rudolf; Khaw, Kay Tee; Lee, I. Min; Le Marchand, Loic; Milne, Roger L.; Peeters, Petra H M; Sund, Malin; Tamimi, Rulla; Trichopoulou, Antonia; Weiderpass, Elisabete; Yang, Xiaohong R.; Prentice, Ross L.; Feigelson, Heather Spencer; Canzian, Federico; Kraft, Peter.

In: Breast Cancer Research and Treatment, Vol. 155, No. 3, 01.02.2016, p. 531-540.

Research output: Contribution to journal › Article

Gaudet, MM, Barrdahl, M, Lindström, S, Travis, RC, Auer, PL, Buring, JE, Chanock, SJ, Heather Eliassen, A, Gapstur, SM, Giles, GG, Gunter, M, Haiman, C, Hunter, DJ, Joshi, AD, Kaaks, R, Khaw, KT, Lee, IM, Le Marchand, L, Milne, RL, Peeters, PHM, Sund, M, Tamimi, R, Trichopoulou, A, Weiderpass, E, Yang, XR, Prentice, RL, Feigelson, HS, Canzian, F & Kraft, P 2016, 'Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium', Breast Cancer Research and Treatment, vol. 155, no. 3, pp. 531-540. https://doi.org/10.1007/s10549-016-3681-7
Gaudet MM, Barrdahl M, Lindström S, Travis RC, Auer PL, Buring JE et al. Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. Breast Cancer Research and Treatment. 2016 Feb 1;155(3):531-540. https://doi.org/10.1007/s10549-016-3681-7
Gaudet, Mia M. ; Barrdahl, Myrto ; Lindström, Sara ; Travis, Ruth C. ; Auer, Paul L. ; Buring, Julie E. ; Chanock, Stephen J. ; Heather Eliassen, A. ; Gapstur, Susan M. ; Giles, Graham G. ; Gunter, Marc ; Haiman, Christopher ; Hunter, David J. ; Joshi, Amit D. ; Kaaks, Rudolf ; Khaw, Kay Tee ; Lee, I. Min ; Le Marchand, Loic ; Milne, Roger L. ; Peeters, Petra H M ; Sund, Malin ; Tamimi, Rulla ; Trichopoulou, Antonia ; Weiderpass, Elisabete ; Yang, Xiaohong R. ; Prentice, Ross L. ; Feigelson, Heather Spencer ; Canzian, Federico ; Kraft, Peter. / Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. In: Breast Cancer Research and Treatment. 2016 ; Vol. 155, No. 3. pp. 531-540.
@article{0f658b2b4c33494b9691455df5e7f52d,
title = "Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium",
abstract = "Current use of menopausal hormone therapy (MHT) has important implications for postmenopausal breast cancer risk, and observed associations might be modified by known breast cancer susceptibility loci. To provide the most comprehensive assessment of interactions of prospectively collected data on MHT and 17 confirmed susceptibility loci with invasive breast cancer risk, a nested case–control design among eight cohorts within the NCI Breast and Prostate Cancer Cohort Consortium was used. Based on data from 13,304 cases and 15,622 controls, multivariable-adjusted logistic regression analyses were used to estimate odds ratios (OR) and 95 {\%} confidence intervals (CI). Effect modification of current and past use was evaluated on the multiplicative scale. P values −3 were considered statistically significant. The strongest evidence of effect modification was observed for current MHT by 9q31-rs865686. Compared to never users of MHT with the rs865686 GG genotype, the association between current MHT use and breast cancer risk for the TT genotype (OR 1.79, 95 {\%} CI 1.43–2.24; Pinteraction = 1.2 × 10−4) was less than expected on the multiplicative scale. There are no biological implications of the sub-multiplicative interaction between MHT and rs865686. Menopausal hormone therapy is unlikely to have a strong interaction with the common genetic variants associated with invasive breast cancer.",
keywords = "Breast cancer, Genetic variation, Menopausal hormone therapy",
author = "Gaudet, {Mia M.} and Myrto Barrdahl and Sara Lindstr{\"o}m and Travis, {Ruth C.} and Auer, {Paul L.} and Buring, {Julie E.} and Chanock, {Stephen J.} and {Heather Eliassen}, A. and Gapstur, {Susan M.} and Giles, {Graham G.} and Marc Gunter and Christopher Haiman and Hunter, {David J.} and Joshi, {Amit D.} and Rudolf Kaaks and Khaw, {Kay Tee} and Lee, {I. Min} and {Le Marchand}, Loic and Milne, {Roger L.} and Peeters, {Petra H M} and Malin Sund and Rulla Tamimi and Antonia Trichopoulou and Elisabete Weiderpass and Yang, {Xiaohong R.} and Prentice, {Ross L.} and Feigelson, {Heather Spencer} and Federico Canzian and Peter Kraft",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s10549-016-3681-7",
language = "English (US)",
volume = "155",
pages = "531--540",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium

AU - Gaudet, Mia M.

AU - Barrdahl, Myrto

AU - Lindström, Sara

AU - Travis, Ruth C.

AU - Auer, Paul L.

AU - Buring, Julie E.

AU - Chanock, Stephen J.

AU - Heather Eliassen, A.

AU - Gapstur, Susan M.

AU - Giles, Graham G.

AU - Gunter, Marc

AU - Haiman, Christopher

AU - Hunter, David J.

AU - Joshi, Amit D.

AU - Kaaks, Rudolf

AU - Khaw, Kay Tee

AU - Lee, I. Min

AU - Le Marchand, Loic

AU - Milne, Roger L.

AU - Peeters, Petra H M

AU - Sund, Malin

AU - Tamimi, Rulla

AU - Trichopoulou, Antonia

AU - Weiderpass, Elisabete

AU - Yang, Xiaohong R.

AU - Prentice, Ross L.

AU - Feigelson, Heather Spencer

AU - Canzian, Federico

AU - Kraft, Peter

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Current use of menopausal hormone therapy (MHT) has important implications for postmenopausal breast cancer risk, and observed associations might be modified by known breast cancer susceptibility loci. To provide the most comprehensive assessment of interactions of prospectively collected data on MHT and 17 confirmed susceptibility loci with invasive breast cancer risk, a nested case–control design among eight cohorts within the NCI Breast and Prostate Cancer Cohort Consortium was used. Based on data from 13,304 cases and 15,622 controls, multivariable-adjusted logistic regression analyses were used to estimate odds ratios (OR) and 95 % confidence intervals (CI). Effect modification of current and past use was evaluated on the multiplicative scale. P values −3 were considered statistically significant. The strongest evidence of effect modification was observed for current MHT by 9q31-rs865686. Compared to never users of MHT with the rs865686 GG genotype, the association between current MHT use and breast cancer risk for the TT genotype (OR 1.79, 95 % CI 1.43–2.24; Pinteraction = 1.2 × 10−4) was less than expected on the multiplicative scale. There are no biological implications of the sub-multiplicative interaction between MHT and rs865686. Menopausal hormone therapy is unlikely to have a strong interaction with the common genetic variants associated with invasive breast cancer.

AB - Current use of menopausal hormone therapy (MHT) has important implications for postmenopausal breast cancer risk, and observed associations might be modified by known breast cancer susceptibility loci. To provide the most comprehensive assessment of interactions of prospectively collected data on MHT and 17 confirmed susceptibility loci with invasive breast cancer risk, a nested case–control design among eight cohorts within the NCI Breast and Prostate Cancer Cohort Consortium was used. Based on data from 13,304 cases and 15,622 controls, multivariable-adjusted logistic regression analyses were used to estimate odds ratios (OR) and 95 % confidence intervals (CI). Effect modification of current and past use was evaluated on the multiplicative scale. P values −3 were considered statistically significant. The strongest evidence of effect modification was observed for current MHT by 9q31-rs865686. Compared to never users of MHT with the rs865686 GG genotype, the association between current MHT use and breast cancer risk for the TT genotype (OR 1.79, 95 % CI 1.43–2.24; Pinteraction = 1.2 × 10−4) was less than expected on the multiplicative scale. There are no biological implications of the sub-multiplicative interaction between MHT and rs865686. Menopausal hormone therapy is unlikely to have a strong interaction with the common genetic variants associated with invasive breast cancer.

KW - Breast cancer

KW - Genetic variation

KW - Menopausal hormone therapy

UR - http://www.scopus.com/inward/record.url?scp=84959107143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959107143&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3681-7

DO - 10.1007/s10549-016-3681-7

M3 - Article

C2 - 26802016

AN - SCOPUS:84959107143

VL - 155

SP - 531

EP - 540

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -

Access to Document